DOJ Places FDA-Approved Marijuana Products in Schedule III

Key Takeaways

• The US Department of Justice (DOJ) has moved US Food and Drug Administration (FDA)-approved marijuana products and certain qualifying cannabis-containing products to Schedule III, recognizing medical use while maintaining federal oversight.
• The change is expected to reduce research barriers, potentially expanding clinical evidence on safety, efficacy, and appropriate therapeutic use.
• For clinicians and payers, the shift may influence future prescribing guidance, formulary decisions, and integration of cannabis-based therapies into managed care.

The Policy Shift

The DOJ has announced that certain marijuana-related products—specifically those approved by the FDA and products containing marijuana under qualifying state licenses—will be placed in Schedule III under the Controlled Substances Act.

This marks a significant departure from marijuana’s longstanding classification as a Schedule I substance, a category reserved for drugs considered to have high abuse potential and no accepted medical use.

Schedule III drugs, by contrast, are recognized as having medical value and are subject to less restrictive regulatory controls, though they remain federally regulated substances.

Key Components of the DOJ Action

• Targeted Scope: The policy applies specifically to FDA-approved marijuana products and certain state-licensed products, not all cannabis broadly.
• Maintained Federal Oversight: Marijuana remains a controlled substance, and federal regulatory frameworks—including the Food, Drug, and Cosmetic Act—continue to apply.
• Research Emphasis: The shift is designed to facilitate more rigorous clinical research into marijuana’s safety and efficacy.

Implications for Managed Care and Payers

1. Expanded Evidence Base

By easing research barriers, Schedule III placement is expected to generate more robust clinical data on cannabis-derived therapies. Historically, limited research has created gaps in prescribing guidance and utilization management.

For payers, this could mean the following:

• More standardized clinical evidence to inform coverage decisions
• Greater clarity on indications, dosing, and safety profiles

2. Coverage and Formulary Considerations

FDA-approved marijuana-based therapies already exist but have faced regulatory complexity due to Schedule I status. Reclassification may do the following:

• Streamline pathways for future FDA approvals
• Increase pressure to evaluate these therapies alongside other Schedule III drugs
• Raise questions about formulary placement and prior authorization criteria

3. Alignment With State Programs

Most states have legalized medical marijuana in some form, creating a longstanding disconnect between federal and state policy.

The DOJ action narrows—but does not eliminate—this gap by:

• Recognizing certain state-licensed products
• Maintaining federal restrictions on non-approved or recreational use

For managed care organizations operating across multiple states, policy alignment remains partial and may continue to complicate benefit design.

4. Regulatory and Compliance Considerations

Despite reclassification, marijuana-related products remain subject to federal controls, including the following:

• Drug Enforcement Administration (DEA) scheduling requirements
• FDA approval and labeling standards
• Ongoing enforcement under federal law

This means payers and providers must still navigate a complex compliance environment, particularly when integrating cannabis-based therapies into care pathways.

What Comes Next

The DOJ’s action is part of a broader federal effort to reassess marijuana policy, including potential further rescheduling considerations.

Future developments could include the following:

• Expanded rescheduling beyond FDA-approved products
• Additional rulemaking or hearings under the Controlled Substances Act
• Continued emphasis on research and clinical validation

The Bottom Line

The DOJ’s decision to place FDA-approved marijuana products in Schedule III represents an incremental but meaningful shift in federal drug policy. For managed care stakeholders, the change primarily affects research, regulatory clarity, and long-term coverage strategy—rather than immediate utilization or access.

As clinical evidence evolves and federal policy continues to develop, payers may need to reassess how cannabis-derived therapies fit within formularies, reimbursement models, and broader population health strategies.

Reference

US Department of Justice. Justice Department places FDA-approved marijuana products and products containing marijuana subject to a qualifying state-issued license in Schedule III, strengthening medical research while maintaining strict federal controls. April 23, 2026. Accessed April 23, 2026. https://files.constantcontact.com/6b6ea99f701/afac72b6-86e9-4ff7-ac94-69c13410c902.pdf